BPC-157 — Body Protection Compound 157, gastric pentadecapeptide

Snapshot

Class: Synthetic peptide fragment — cytoprotective / tissue-protective
Evidence tier: Animal-only evidence
Status: Not FDA approved for any indication. Not authorized by EMA, MHRA, or Health Canada. Removed from FDA 503A category 2 compounding list (April 22, 2026; nominations withdrawn). FDA has stated intent to consult the PCAC on July 23, 2026 regarding BPC-157 acetate and free-base forms — outcome pending. Classified as Schedule 4 prescription-only by Australia's TGA; enforcement action documented against unapproved sale. Prohibited by WADA under S0 (non-approved substances for human therapeutic use, 2022 update); multiple athlete sanctions documented.

Best-supported effect: Accelerated tendon, ligament, and gut mucosal healing in rodent models; animal evidence spans multiple organ systems. Human efficacy is unestablished — no published controlled human trial for any indication has been completed.

Main caveat: No published human efficacy RCT for any indication. All therapeutic claims derive from animal models. The concentration of research in a single laboratory is an additional caveat for interpreting effect sizes in the preclinical literature.

What this is

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide. It is a partial sequence (positions 1–15) of a larger protein first isolated from human gastric juice in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, Croatia. The full parent protein was named Body Protection Compound for its apparent protective effects on the stomach lining. The isolated fragment was found to retain biological activity and is unusually resistant to enzymatic degradation — due in part to a polyproline motif at positions 3–5 — which contributes to its stability and oral bioavailability relative to most peptides.

Also known as: Body Protection Compound-157, Bepecin, PL 14736, PL-10, Pentadecapeptide.

The peptide was the subject of a Phase II clinical trial for inflammatory bowel disease sponsored by Croatian pharmaceutical company Pliva (development code PL-14736). Partial results were published; the program was abandoned after Teva acquired Pliva.

Chemistry

The polyproline motif (Pro-Pro-Pro at positions 3–5) confers resistance to proteolytic cleavage, making the peptide unusually stable compared to most short peptides. Human oral bioavailability data are not individually extracted's available literature.

Mechanism

BPC-157 does not act through a single receptor. Research multiple interconnected pathways documented in animal models and cell assays:

• VEGF, EGF, FGF, HGF upregulation — promotes angiogenesis and tissue granulation at injury sites in rodent models
• eNOS / nitric oxide system modulation — vasodilation and blood flow regulation; cytoprotective effects described across organ systems in animal models [R3]
• FAK-paxillin pathway — promotes fibroblast migration to damage sites; characterized in tendon fibroblast scratch assays [R1]
• Dopamine system (D1/D2) — attenuation of haloperidol-induced catalepsy in rats suggests D2 receptor pathway involvement [R4]
• 5-HT2 serotonergic effects — described in rat gastric ulcer models [R5]

Sikiric's group has described these convergent effects as "cytoprotection" — a broad protective program across organ systems. which of these pathways are primary drivers of observed healing vs. secondary correlates remains unresolved.

Evidence map

Replication note: The large majority of animal evidence originates from the Sikiric laboratory or direct collaborators. Independent replication exists but is limited. This single-laboratory concentration is a recognized limitation for interpreting effect size confidence in the preclinical literature. A 2026 systematic review (Vasireddi et al.) confirmed the musculoskeletal healing signal across 35 preclinical studies but flagged the absence of human controlled data [R7].

Claim check

Experimental exposure

No controlled human efficacy trial has been completed for any indication. The following represents the extent of human exposure data in the available literature.

Preclinical animal doses used in published studies typically range from 10–500 µg/kg administered intraperitoneally, intragastrically, or subcutaneously in rodent models. Animal dosing is not extracted for human comparison in this card.

Safety signals

From animal studies: No lethal dose has been established in rodent studies at doses far exceeding reported therapeutic ranges. per available sources preclinical safety assessment (Xu et al., 2020) found no evidence of hormonal suppression, HPA axis effects, or organ growth [R6].

From human pilot data: Lee & Burgess 2025 (n=2 IV) reported no adverse events on any assessed biomarker. Community self-report aggregations in available literature describe injection-site soreness as the most commonly cited adverse event; mild nausea (oral route) and transient dizziness are also reported.

Theoretical concern — angiogenic activity: BPC-157 upregulates VEGF and other angiogenic growth factors. Source notes this raises a theoretical concern for tumor promotion in individuals with active malignancy or recent cancer history. Source states this concern has not been observed in animal studies but has not been formally addressed by long-duration rodent carcinogenicity studies or human pharmacovigilance.

Theoretical concern — anti-angiogenic drug interaction: Source describes a theoretical interaction with anti-angiogenic oncology therapies (bevacizumab, VEGF-pathway tyrosine kinase inhibitors) and anti-angiogenic ophthalmologic agents. Mechanism-based opposition is the basis; no controlled interaction data are extracted in this card.

Quality/purity signal: BPC-157 is primarily sold as a gray-market research compound. University laboratory testing of gray-market vials has documented bacterial endotoxin contamination, incorrect molecular weight, and in some cases incorrect peptide identity. Source frames this as the primary practical safety concern for community users, distinct from the molecule's intrinsic risk profile.

Regulatory status

The PCAC review scheduled for July 23, 2026 is relevant to US compounding eligibility; outcome is pending at the time the available literature was compiled.

Clinical trials

Community patterns

This section describes reported off-label use patterns from the available literature. These are not clinically validated protocols.

Source notes that community use patterns — injection localized near injury sites with reported improvement — correspond directionally to the animal model signal. Survivorship bias is explicitly flagged in available literature as severe.

Open questions

From the available literature:

• Long-term human safety — no study extends beyond short observational windows at any dose or route
• Human pharmacokinetics — absorption, distribution, metabolism, and excretion characterized only in rodents; route-comparative bioavailability (oral vs. subcutaneous vs. IV) unresolved in humans
• Carcinogenicity — VEGF upregulation raises a theoretical tumor-promotion concern; not addressed by long-duration rodent carcinogenicity studies
• Independent replication — large majority of preclinical publications originate from Sikiric's group; independent effect-size confirmation from other labs is needed
• Mechanism specificity — primary vs. secondary pathway among VEGF/angiogenesis, NO system, FAK-paxillin, dopaminergic, and serotonergic effects is unresolved
• Patent and funding gap — source describes expired or contested patents on the core molecule as a structural barrier to industry-funded FDA trials; this is noted as the economic explanation for the absence of Phase III data after three decades of preclinical work